Physician profile
Matthew Thomas Manzo
NPI 1376591636
$3,489.83
in general payments reported to CMS, 2019-2025
28 companies · $693 in 2025
The $693 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $258 · 2021: $566 · 2022: $461 · 2023: $455 · 2024: $204 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,036.28 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $461.86 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $300.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $195.20 | 2019-2024 | Prolia, Evenity, Otezla |
| Sanofi-Aventis U.S. LLC | $192.09 | 2019-2022 | |
| Abbvie INC. | $186.62 | 2023-2025 | |
| Exact Sciences Corporation | $171.50 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.36 | 2020-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $99.18 | 2019-2023 | Trintellix |
| Glaxosmithkline, LLC. | $91.42 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $74.97 | 2025 | Purified Cortrophin Gel |
| Pfizer INC. | $64.15 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.14 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $52.71 | 2023-2024 | Gvoke Hypopen |
| Edwards Lifesciences Corporation | $48.26 | 2021-2025 | Sapien 3 Ultra Resilia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $48.20 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $43.02 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.19 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $34.37 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.14 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $26.22 | 2020 | |
| Phathom Pharmaceuticals, INC. | $25.83 | 2025 | Voquezna |
| Sanofi Pasteur INC. | $19.60 | 2019 | |
| Collegium Pharmaceutical, INC. | $19.07 | 2023 | Xtampza |
| Amarin Pharma, INC. | $15.93 | 2021 | |
| Astellas Pharma US INC | $15.72 | 2025 | Veozah |
| Shire North American Group INC | $15.35 | 2019 | |
| Aytu Biopharma, INC. | $14.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Manzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.